Briggs W. Morrison, M.D., as served as our President, Head of Research and Development since February 2022 and previously served as our Chief Executive Officer since June 2015 and as a member of our board of directors since July 2015. Dr. Morrison currently serves as a managing director of MPM Capital, a healthcare-focused venture capital firm, since June 2015. Prior to joining us, he served as Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca plc, a publicly traded company, from January 2012 to June 2015, leading the company’s global, late-stage development organization and serving as a member of the AstraZeneca senior executive team. He previously held a number of positions at Pfizer Inc., a publicly traded company, from 2007 to January 2012 that culminated in his appointment as Head, Medical Affairs, Safety and Regulatory Affairs for Pfizer’s human health business, and also served in roles of increasing responsibility at Merck Research Laboratories, a division of Merck & Co., Inc., from 1995 to 2007, ascending to the role of Vice President, Clinical Sciences, Oncology, responsible for clinical development of all novel anti-cancer drugs. Dr. Morrison currently serves on the board of Arvinas, Repare Therapeutics and Werewolf Therapeutics, each of which is a publicly traded company, as well as the boards of several private companies. Previously, he served on the board of Codiak Biosciences, Oncorus and NextCure Therapeutics. Dr. Morrison received a B.S. in biology from Georgetown University and an M.D. from the University of Connecticut.
What is Briggs Morrison's net worth?
The estimated net worth of Briggs Morrison is at least $954.06 thousand as of September 22nd, 2025. Dr. Morrison owns 76,021 shares of Arvinas stock worth more than $954,064 as of December 4th. This net worth evaluation does not reflect any other investments that Dr. Morrison may own. Learn More about Briggs Morrison's net worth.
How do I contact Briggs Morrison?
Has Briggs Morrison been buying or selling shares of Arvinas?
Briggs Morrison has not been actively trading shares of Arvinas during the last ninety days. Most recently, on Monday, September 22nd, Briggs Morrison bought 30,000 shares of Arvinas stock. The stock was acquired at an average cost of $7.57 per share, with a total value of $227,100.00. Following the completion of the transaction, the director now directly owns 76,021 shares of the company's stock, valued at $575,478.97. Learn More on Briggs Morrison's trading history.
Who are Arvinas' active insiders?
Are insiders buying or selling shares of Arvinas?
In the last year, Arvinas insiders bought shares 1 times. They purchased a total of 30,000 shares worth more than $227,100.00. In the last year, insiders at the sold shares 6 times. They sold a total of 56,160 shares worth more than $815,053.98. The most recent insider tranaction occured on November, 7th when CAO David K Loomis sold 230 shares worth more than $2,274.70. Insiders at Arvinas own 4.7% of the company.
Learn More about insider trades at Arvinas. Information on this page was last updated on 11/7/2025.
